Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder

Chi Shin Wu, Ming H. Hsieh, Chao Hsiun Tang, Ching Jui Chang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective The aim of this study was to compare the treatment effectiveness between long-acting injectable risperidone and long-acting injectable first-generation antipsychotics among patients with bipolar disorder. Method We conducted a retrospective cohort study using Taiwan's National Health Insurance Research Database. Patients with bipolar disorder aged 15 years or higher, who were newly administered long-acting injectable antipsychotics between June 1, 2004 and December 31, 2011 were included. The clinical outcome indexes were hospitalization for any mood, manic/mixed, or depressive episodes. In addition, the all-cause discontinuation of long-acting injectable antipsychotic treatment was also assessed. Results A total of 3916 patients with bipolar disorder were extracted. Compared with risperidone, the use of first-generation antipsychotics was associated with a higher rate of hospitalization for any mood episode and major depressive episode. However, there was no statistically significant difference in treatment discontinuation rate between risperidone and first-generation antipsychotics. Limitations Information for the severity of mood symptoms, social support, life style, neurological and metabolic adverse effect was not available in this database. In addition, we only measured severe mood episodes with hospitalization as our outcome index. It may not be possible to generalize our findings to mild mood episodes. Conclusions Our findings suggested that patients treated with long-acting injectable risperidone might be superior to first-generation antipsychotics in the rate of psychiatric hospitalization.

Original languageEnglish
Pages (from-to)189-195
Number of pages7
JournalJournal of Affective Disorders
Volume197
DOIs
Publication statusPublished - Jun 1 2016

Fingerprint

Risperidone
Bipolar Disorder
Antipsychotic Agents
Injections
Hospitalization
Databases
National Health Programs
Taiwan
Social Support
Psychiatry
Life Style
Cohort Studies
Retrospective Studies
Therapeutics
Research

Keywords

  • Bipolar disorder
  • First-generation antipsychotics
  • Long-acting injectable antipsychotics
  • Risperidone

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder. / Wu, Chi Shin; Hsieh, Ming H.; Tang, Chao Hsiun; Chang, Ching Jui.

In: Journal of Affective Disorders, Vol. 197, 01.06.2016, p. 189-195.

Research output: Contribution to journalArticle

@article{eb3ba4cd5abf4479ae20d0a532847c53,
title = "Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder",
abstract = "Objective The aim of this study was to compare the treatment effectiveness between long-acting injectable risperidone and long-acting injectable first-generation antipsychotics among patients with bipolar disorder. Method We conducted a retrospective cohort study using Taiwan's National Health Insurance Research Database. Patients with bipolar disorder aged 15 years or higher, who were newly administered long-acting injectable antipsychotics between June 1, 2004 and December 31, 2011 were included. The clinical outcome indexes were hospitalization for any mood, manic/mixed, or depressive episodes. In addition, the all-cause discontinuation of long-acting injectable antipsychotic treatment was also assessed. Results A total of 3916 patients with bipolar disorder were extracted. Compared with risperidone, the use of first-generation antipsychotics was associated with a higher rate of hospitalization for any mood episode and major depressive episode. However, there was no statistically significant difference in treatment discontinuation rate between risperidone and first-generation antipsychotics. Limitations Information for the severity of mood symptoms, social support, life style, neurological and metabolic adverse effect was not available in this database. In addition, we only measured severe mood episodes with hospitalization as our outcome index. It may not be possible to generalize our findings to mild mood episodes. Conclusions Our findings suggested that patients treated with long-acting injectable risperidone might be superior to first-generation antipsychotics in the rate of psychiatric hospitalization.",
keywords = "Bipolar disorder, First-generation antipsychotics, Long-acting injectable antipsychotics, Risperidone",
author = "Wu, {Chi Shin} and Hsieh, {Ming H.} and Tang, {Chao Hsiun} and Chang, {Ching Jui}",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.jad.2016.03.043",
language = "English",
volume = "197",
pages = "189--195",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",

}

TY - JOUR

T1 - Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder

AU - Wu, Chi Shin

AU - Hsieh, Ming H.

AU - Tang, Chao Hsiun

AU - Chang, Ching Jui

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Objective The aim of this study was to compare the treatment effectiveness between long-acting injectable risperidone and long-acting injectable first-generation antipsychotics among patients with bipolar disorder. Method We conducted a retrospective cohort study using Taiwan's National Health Insurance Research Database. Patients with bipolar disorder aged 15 years or higher, who were newly administered long-acting injectable antipsychotics between June 1, 2004 and December 31, 2011 were included. The clinical outcome indexes were hospitalization for any mood, manic/mixed, or depressive episodes. In addition, the all-cause discontinuation of long-acting injectable antipsychotic treatment was also assessed. Results A total of 3916 patients with bipolar disorder were extracted. Compared with risperidone, the use of first-generation antipsychotics was associated with a higher rate of hospitalization for any mood episode and major depressive episode. However, there was no statistically significant difference in treatment discontinuation rate between risperidone and first-generation antipsychotics. Limitations Information for the severity of mood symptoms, social support, life style, neurological and metabolic adverse effect was not available in this database. In addition, we only measured severe mood episodes with hospitalization as our outcome index. It may not be possible to generalize our findings to mild mood episodes. Conclusions Our findings suggested that patients treated with long-acting injectable risperidone might be superior to first-generation antipsychotics in the rate of psychiatric hospitalization.

AB - Objective The aim of this study was to compare the treatment effectiveness between long-acting injectable risperidone and long-acting injectable first-generation antipsychotics among patients with bipolar disorder. Method We conducted a retrospective cohort study using Taiwan's National Health Insurance Research Database. Patients with bipolar disorder aged 15 years or higher, who were newly administered long-acting injectable antipsychotics between June 1, 2004 and December 31, 2011 were included. The clinical outcome indexes were hospitalization for any mood, manic/mixed, or depressive episodes. In addition, the all-cause discontinuation of long-acting injectable antipsychotic treatment was also assessed. Results A total of 3916 patients with bipolar disorder were extracted. Compared with risperidone, the use of first-generation antipsychotics was associated with a higher rate of hospitalization for any mood episode and major depressive episode. However, there was no statistically significant difference in treatment discontinuation rate between risperidone and first-generation antipsychotics. Limitations Information for the severity of mood symptoms, social support, life style, neurological and metabolic adverse effect was not available in this database. In addition, we only measured severe mood episodes with hospitalization as our outcome index. It may not be possible to generalize our findings to mild mood episodes. Conclusions Our findings suggested that patients treated with long-acting injectable risperidone might be superior to first-generation antipsychotics in the rate of psychiatric hospitalization.

KW - Bipolar disorder

KW - First-generation antipsychotics

KW - Long-acting injectable antipsychotics

KW - Risperidone

UR - http://www.scopus.com/inward/record.url?scp=84961206787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961206787&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2016.03.043

DO - 10.1016/j.jad.2016.03.043

M3 - Article

C2 - 26994437

AN - SCOPUS:84961206787

VL - 197

SP - 189

EP - 195

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

ER -